Baduanjin Lower Elevated Blood PreSsure Study

Last updated: September 3, 2025
Sponsor: China National Center for Cardiovascular Diseases
Overall Status: Completed

Phase

N/A

Condition

Vascular Diseases

Williams Syndrome

Stress

Treatment

Brisk walking

Baduanjin

Clinical Study ID

NCT05397535
2022-1724
  • Ages > 40
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The aim of this study is to evaluate the effects of Baduanjin on blood pressure in individuals with high normal blood pressure (SBP 130-139 mmHg, and/or DBP 85-89 mmHg), as well as on glucose and lipid metabolism, quality of life, psychology, exercise, immune inflammation, endothelial function, and arterial stiffness.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 40 years or older;

  • Systolic blood pressure (SBP) <140 mmHg and diastolic blood pressure (DBP) <90 mmHg

  • SBP 130-139 mmHg, and/or DBP 85-89 mmHg

Exclusion

Exclusion Criteria:

  • Diagnosis of hypertension (SBP≥140 mmHg, and/or DBP ≥90mmHg)

  • History of cardiovascular diseases, such as coronary heart disease, heart failure,stroke, and peripheral vascular disease

  • Diagnosis of chronic kidney disease, primary aldosteronism, Cushing's syndrome, orpheochromocytoma

  • Newly diagnosed cancer or cancer metastasis within 5 years

  • History of autoimmune disease

  • Having taken antihypertensive drugs or immunoregulators within 2 weeks

  • A long-term need for antihypertensive drugs or immunomoregulators

  • Unable to maintain moderate intensity exercise due to illness or other reasons

  • Pregnant, breastfeeding, or planning to become pregnant within the next 1 year

  • Currently taking regular exercise (at least 30 minutes of moderate-intensityexercise at least three times a week)

  • Allergic to sports bracelets

  • Having participated or been participating in other clinical trials within the last 3months

  • Unable to use smartphones

  • Other factors that may affect the follow-up, such as alcohol or substance abuse inthe last 12 months, planing to live out of town for a long time, or diagnosis ofdementia or cognitive impairment which indicates incapability of completing thestudy

  • Unable to accurately measure blood pressure using the sphygmomanometer provided bythe study due to a too large or too small arm circumference

Study Design

Total Participants: 216
Treatment Group(s): 2
Primary Treatment: Brisk walking
Phase:
Study Start date:
June 05, 2022
Estimated Completion Date:
July 11, 2025

Connect with a study center

  • Fuwai Hospital

    Beijing, Beijing
    China

    Site Not Available

  • Fuwai Hospital

    Beijing 1816670, Beijing Municipality 2038349
    China

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.